Okyo Pharma has submitted an investigational new drug application to the FDA for OK-101 for the treatment of dry eye disease.
OK-101, a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein, is designed to prevent washout in dry eye disease by using a lipid “anchor” to enhance the residence time of OK-101 in the ocular environment, according to a press release.
The FDA previously agreed to a first-in-human phase 2 trial of OK-101 that will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of dry eye disease.
“The filing of this